Revance Therapeutics Inc (RVNC)

17.85
NASDAQ : Health Care
Prev Close 17.85
Day Low/High 0.00 / 0.00
52 Wk Low/High 12.35 / 39.26
Avg Volume 205.80K
Exchange NASDAQ
Shares Outstanding 28.52M
Market Cap 507.57M
EPS -3.00
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Revance Releases Third Quarter 2016 Results

Revance Releases Third Quarter 2016 Results

Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced results for the third quarter ended September 30, 2016.

Revance Announces Initiation Of Phase 2 Trial Of RT002 Injectable To Treat Plantar Fasciitis

Revance Announces Initiation Of Phase 2 Trial Of RT002 Injectable To Treat Plantar Fasciitis

Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced initiation of a Phase 2 placebo-controlled trial of its...

Revance Therapeutics To Release Third Quarter 2016 Financial Results Thursday, November 3, 2016

Revance Therapeutics To Release Third Quarter 2016 Financial Results Thursday, November 3, 2016

Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced that the company will release third quarter 2016...

Commit To Buy Revance Therapeutics At $10, Earn 10.1% Annualized Using Options

Commit To Buy Revance Therapeutics At $10, Earn 10.1% Annualized Using Options

Investors considering a purchase of Revance Therapeutics Inc shares, but tentative about paying the going market price of $15.64/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the April 2017 put at the $10 strike, which has a bid at the time of this writing of 55 cents.

Revance To Participate In The 2016 Wells Fargo Securities Healthcare Conference

Revance To Participate In The 2016 Wells Fargo Securities Healthcare Conference

Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced that the company will participate in the 2016 Wells...

Revance Releases Second Quarter 2016 Results

Revance Releases Second Quarter 2016 Results

Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced results for the second quarter ended June 30, 2016.

Revance Therapeutics To Release Second Quarter 2016 Financial Results Thursday, August 4, 2016

Revance Therapeutics To Release Second Quarter 2016 Financial Results Thursday, August 4, 2016

Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced that the company will release second quarter 2016...

These 5 Stocks Are Primed for Breakouts

These 5 Stocks Are Primed for Breakouts

Here's a technical look at how to trade five stocks triggering breakout trades.

Revance Announces Completion Of Pre-Phase 3 Meeting With FDA For RT002 Injectable To Treat Glabellar Lines

Revance Announces Completion Of Pre-Phase 3 Meeting With FDA For RT002 Injectable To Treat Glabellar Lines

Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced the completion of its Type B / pre-IND / pre-Phase 3...

Short Interest In Revance Therapeutics Makes 16.2% Move

Short Interest In Revance Therapeutics Makes 16.2% Move

The most recent short interest data has been released for the 06/30/2016 settlement date, which shows a 578,947 share increase in total short interest for Revance Therapeutics Inc , to 4,144,315, an increase of 16.24% since 06/15/2016. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Commit To Buy Revance Therapeutics At $10, Earn 15.2% Annualized Using Options

Commit To Buy Revance Therapeutics At $10, Earn 15.2% Annualized Using Options

Investors eyeing a purchase of Revance Therapeutics Inc shares, but cautious about paying the going market price of $13.21/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the October put at the $10 strike, which has a bid at the time of this writing of 45 cents.

Revance Appoints Industry Leader Julian S. Gangolli To Its Board Of Directors

Revance Appoints Industry Leader Julian S. Gangolli To Its Board Of Directors

Revance Therapeutics, Inc. (NASDAQ: RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced that Julian S.

Revance Therapeutics Becomes Oversold (RVNC)

Revance Therapeutics Becomes Oversold (RVNC)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Revance Therapeutics (RVNC) Stock Plunging on Drug Results

Revance Therapeutics (RVNC) Stock Plunging on Drug Results

Shares of Revance Therapeutics (RVNC) are lower on heavy trading volume Tuesday after the company reported disappointing results for its new drug to treat crow's feat.

Revance Reports Results For RT001 Topical Phase 3 Trial For Lateral Canthal Lines

Revance Reports Results For RT001 Topical Phase 3 Trial For Lateral Canthal Lines

Revance to host conference call at 1:30 pm PDT (4:30 pm EDT) today

Revance Therapeutics To Release First Quarter 2016 Financial Results Monday, May 9, 2016

Revance Therapeutics To Release First Quarter 2016 Financial Results Monday, May 9, 2016

Conference Call Scheduled for Monday, May 9, 2016 at 4:30pm ET

'Mad Money' Lightning Round: Ciena Is Dead

'Mad Money' Lightning Round: Ciena Is Dead

Cramer says ConocoPhillips is good but Occidental Petroleum is better.

Jim Cramer's 'Mad Money' Recap: Here Are Today's Top 10 Winning Stocks

Jim Cramer's 'Mad Money' Recap: Here Are Today's Top 10 Winning Stocks

Looking at this list, you realize things turned out to be a lot better than many of the bears had feared, Cramer says.

Allergan Could Buy These Drug Companies Now That the Pfizer Merger Is Scuttled

Allergan Could Buy These Drug Companies Now That the Pfizer Merger Is Scuttled

Now that the Allergan-Pfizer merger is off, Allergan CEO Saunders could start shopping again for biotech and smaller pharma companies to fuel his company's growth.

Commit To Buy Revance Therapeutics At $17.50, Earn 51.6% Annualized Using Options

Commit To Buy Revance Therapeutics At $17.50, Earn 51.6% Annualized Using Options

Investors considering a purchase of Revance Therapeutics Inc stock, but tentative about paying the going market price of $18.77/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the July put at the $17.50 strike, which has a bid at the time of this writing of $2.50.

5 Earnings Stocks Everyone Else Hates -- but You Should Love

5 Earnings Stocks Everyone Else Hates -- but You Should Love

These heavily shorted stocks could get squeezed much higher if they report positive earnings this week.